Trial Profile
A multicenter, randomized, double-blind, placebo-controlled study of subcutaneous Tovaxin in subjects with CIS or RR-MS.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2016
Price :
$35
*
At a glance
- Drugs Imilecleucel-T (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- Acronyms OLETERMS; OLTERMS; TERMS
- Sponsors Opexa Therapeutics
- 14 Nov 2011 Results of the TERMS study were published in the Multiple Sclerosis Journal, according to an Opexa media release.
- 28 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 28 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.